Cargando…

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data

BACKGROUND: This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that crosses the blood–brain barrier. METHODS: Part A assessed the safety and efficacy of marizomib monotherapy. In Par...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bota, Daniela A, Mason, Warren, Kesari, Santosh, Magge, Rajiv, Winograd, Benjamin, Elias, Ileana, Reich, Steven D, Levin, Nancy, Trikha, Mohit, Desjardins, Annick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557653/ https://www.ncbi.nlm.nih.gov/pubmed/34729484 http://dx.doi.org/10.1093/noajnl/vdab142

Ejemplares similares

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo
por: Manton, Christa A., et al.
Publicado: (2016)

Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma
por: Bazou, Despina, et al.
Publicado: (2020)

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
por: Raninga, Prahlad V., et al.
Publicado: (2020)

Mechanisms of EGFR Resistance in Glioblastoma
por: Pan, Peter C., et al.
Publicado: (2020)

Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist
por: Boccellato, Chiara, et al.
Publicado: (2021)

Targeting mitochondrial energetics reverses panobinostat‐ and marizomib‐induced resistance in pediatric and adult high‐grade gliomas
por: Jane, Esther P., et al.
Publicado: (2023)

Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo
por: Zhang, Ziruizhuo, et al.
Publicado: (2022)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Advances in Radiotherapy for Glioblastoma
por: Mann, Justin, et al.
Publicado: (2018)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Improved Pathologic Diagnosis—Forecasting the Future in Glioblastoma
por: Pisapia, David J., et al.
Publicado: (2017)

Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
por: Potts, Barbara C., et al.
Publicado: (2010)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?
por: Carrillo, Jose A., et al.
Publicado: (2019)

Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

WNT Signaling as a Therapeutic Target for Glioblastoma
por: Latour, Michael, et al.
Publicado: (2021)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts
por: Bota, Daniela A, et al.
Publicado: (2018)

Spinal Dissemination of Intracranial Glioblastoma in Bevacizumab Era: a Potential Bevacizumab-induced Mechanism
por: Kaloshi, Gentian, et al.
Publicado: (2014)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases
por: Fiorentini, Giammaria, et al.
Publicado: (2021)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010)

Histopathological investigation of glioblastomas resected under bevacizumab treatment
por: Tamura, Ryota, et al.
Publicado: (2016)

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2017)

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2018)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
por: García-Romero, N., et al.
Publicado: (2020)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2020)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Diffusion Weighted/Tensor Imaging, Functional MRI and Perfusion Weighted Imaging in Glioblastoma—Foundations and Future
por: Salama, Gayle R., et al.
Publicado: (2018)

Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes
por: Bovi, Joseph A., et al.
Publicado: (2020)

Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM
por: Farid, Nikdokht, et al.
Publicado: (2013)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rddecu60la9hch03i7iiu31698